SVB Leerink Lowers Myovant Sciences (NYSE:MYOV) Price Target to $12.00

Myovant Sciences (NYSE:MYOV – Get Rating) had its price objective decreased by SVB Leerink from $19.00 to $12.00 in a report issued on Wednesday, Marketbeat reports. The firm presently has a “market perform” rating on the stock. SVB Leerink’s price objective would indicate a potential upside of 5.91% from the stock’s previous close.

Several other research analysts have also recently commented on the company. Robert W. Baird lowered their target price on Myovant Sciences from $30.00 to $20.00 in a research note on Wednesday. StockNews.com assumed coverage on Myovant Sciences in a research report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, Zacks Investment Research cut Myovant Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, March 23rd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $22.00.

MYOV stock opened at $11.33 on Wednesday. The company has a market capitalization of $1.06 billion, a PE ratio of -4.59 and a beta of 2.74. Myovant Sciences has a 12-month low of $10.01 and a 12-month high of $27.43. The business’s fifty day moving average price is $13.13 and its 200 day moving average price is $16.18.

Myovant Sciences (NYSE:MYOV – Get Rating) last posted its quarterly earnings data on Wednesday, January 26th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.09). The company had revenue of $54.44 million during the quarter, compared to analysts’ expectations of $54.50 million. During the same quarter in the previous year, the company earned ($0.82) EPS. Sell-side analysts expect that Myovant Sciences will post -2.17 EPS for the current fiscal year.

In other news, insider Ferreira Juan Camilo Arjona sold 1,922 shares of the stock in a transaction that occurred on Tuesday, April 5th. The stock was sold at an average price of $13.78, for a total transaction of $26,485.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Matthew Lang sold 2,436 shares of the firm’s stock in a transaction that occurred on Tuesday, April 5th. The shares were sold at an average price of $13.78, for a total value of $33,568.08. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,240 shares of company stock valued at $351,921. Company insiders own 5.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Credit Suisse AG increased its stake in Myovant Sciences by 2.3% in the 3rd quarter. Credit Suisse AG now owns 26,642 shares of the company’s stock valued at $598,000 after purchasing an additional 587 shares in the last quarter. Torray LLC increased its stake in Myovant Sciences by 0.8% in the 3rd quarter. Torray LLC now owns 74,305 shares of the company’s stock valued at $1,667,000 after purchasing an additional 601 shares in the last quarter. Swiss National Bank increased its stake in Myovant Sciences by 1.0% in the 3rd quarter. Swiss National Bank now owns 80,900 shares of the company’s stock valued at $1,815,000 after purchasing an additional 800 shares in the last quarter. California State Teachers Retirement System grew its holdings in Myovant Sciences by 3.8% during the 4th quarter. California State Teachers Retirement System now owns 31,104 shares of the company’s stock valued at $484,000 after buying an additional 1,133 shares during the last quarter. Finally, Dark Forest Capital Management LP acquired a new stake in shares of Myovant Sciences during the third quarter worth $32,000. 33.78% of the stock is owned by hedge funds and other institutional investors.

Myovant Sciences Company Profile (Get Rating)

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Read More